ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Yuyuan Bioscience Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis:
Investegate announcements from ObsEva SA, ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
-Linzagolix for uterine fibroids: US NDA Q3:22 PDUFA date; Positive CHMP opinion- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the